Optimization of the first small-molecule relaxin/insulin-like family peptide receptor (RXFP1) agonists: Activation results in an antifibrotic gene expression profile.
Eur J Med Chem
; 156: 79-92, 2018 Aug 05.
Article
em En
| MEDLINE
| ID: mdl-30006176
A dose responsive quantitative high throughput screen (qHTS) of >350,000 compounds against a human relaxin/insulin-like family peptide receptor (RXFP1) transfected HEK293â¯cell line identified 2-acetamido-N-phenylbenzamides 1 and 3 with modest agonist activity. An extensive structure-activity study has been undertaken to optimize the potency, efficacy, and physical properties of the series, resulting in the identification of compound 65 (ML-290), which has excellent in vivo PK properties with high levels of systemic exposure. This series, exemplified by 65, has produced first-in-class small-molecule agonists of RXFP1 and is a potent activator of anti-fibrotic genes.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Benzamidas
/
Receptores de Peptídeos
/
Receptores Acoplados a Proteínas G
/
Células Estreladas do Fígado
/
Transcriptoma
Idioma:
En
Ano de publicação:
2018
Tipo de documento:
Article